Print

Biodesix, Inc. Announces Phase 3 Clinical Trial Collaboration with Kadmon Pharmaceuticals  
2/27/2012 6:30:18 AM

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced a collaboration with Kadmon Corporation, LLC, to explore the utility of Biodesix’ VeriStrat® test in a Phase 3 non-small cell lung cancer (NSCLC) study of Kadmon’s KD019, a reversible tyrosine kinase inhibitor (TKI) targeting EGFR, HER2, VEGFR2 & 3, and SRC.
//-->